Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLUR vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: PLUR 2 – 3 IMMX (1 Tie) Matrix Metrics: PLUR 2 – 7 IMMX

As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas IMMX carries 53.1/100 (HOLD) at $7.23 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUR vs IMMX
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.23
-3.34% 1D
Market Cap $657.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.83β · 83% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $7.96 · SMA50: $9.57

6-Pillar Scorecard Institutional Category Breakdown (PLUR 2 – 3 IMMX)

Columns: Metric · PLUR · IMMX
1. Valuation Multiples PLUR
Forward P/E 3.6x N/M
Trailing P/E 3.6x N/M
PEG Ratio N/M N/M
EV / Revenue 44.6x N/M
2. Growth & Scale IMMX
Revenue Growth (YoY) -15.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.0M N/A
Market Cap $15.1M $657.1M
3. Profitability & Quality IMMX
Gross Margin 44.6% N/A
Operating Margin -2454.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1022.0% -27.0%
4. Balance Sheet & Cash Flow IMMX
Cash Generation (TTM) -$22M -$39M
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Debt $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PLUR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 92.6% (17th %ile)
Put/Call OI Skew N/A 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUR (2) vs IMMX (7)
Institutional Metric PLUR IMMX Criterion Row Edge
Market Capitalization
Scale
$15.1M $657.1M Larger Scale IMMX
Trailing P/E Ratio
Valuation
3.6x N/M Lower Multiple PLUR
Forward P/E Ratio
Valuation
3.6x N/M Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-15.8% +0.0% Higher Growth IMMX
Operating Margin (TTM)
Profitability
-2454.5% 0.0% Higher Margin IMMX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1022.0% -27.0% Higher ROE IMMX
52-Week Range Position
Momentum
2% ($1–$5) 32% ($4–$15) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
0.80β · 102% Vol 1.83β · 83% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 53.1 / 100 (HOLD) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
$1.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 44.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($30M Net Debt) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +23.13 pp
PLUR: +11.09% · IMMX: -12.04%
3M Horizon IMMX +1.15 pp
PLUR: -46.34% · IMMX: -45.19%
6M Horizon IMMX +44.12 pp
PLUR: -62.52% · IMMX: -18.4%
1Y Horizon IMMX +147.26 pp
PLUR: -75.53% · IMMX: +71.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs IMMX. Trailing 12-month operating profitability (PLUR -2454.5% vs IMMX 0.0%) and valuation multiples (PLUR 3.6x vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PLUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin44.6%
Op. Margin-2454.5%
ROE / Fwd P/E-1022.0% · 3.6x
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLUR vs IMMX Key Questions & Quantitative Answers

As of Nov 17, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas IMMX carries 53.1/100 (HOLD) at $7.23 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMX leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PLUR generates $1.0M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

PLUR screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.